Chengda Pharmaceuticals (301201) Revenue Breakdown - Main Composition

44.57
-0.67-1.48%

Market Closed Mar 11 15:00 CST

6.90BMarket Cap-133.44P/E (TTM)

Chengda Pharmaceuticals (301201) Revenue Breakdown Overview

By Product

Currency:CNY

2025/H1

Stock NameRevenueRatio

自主销售类产品收入109.7M60.13%

定制类产品和服务收入70.35M38.56%

Total special adjustments1.61M0.88%

Other business794.04K0.44%

By Industry

Currency:CNY

2024/FY

Stock NameRevenueRatio

Pharmaceutical manufacturing industry185.46M55.67%

Food manufacturing industry143.23M43.00%

Other business2.28M0.69%

贸易类收入2.15M0.65%

By Country/Region

Currency:CNY

2024/FY

Stock NameRevenueRatio

Domestic223.5M67.09%

Abroad109.63M32.91%

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

Recently, the ongoing conflict between the US and Iran has continued to impact the stock market. Previously, there were indications that Tru Show More

富哥搞钱

Feb 28 17:22

Breaking! The US and Israel jointly bombed Iran. What will be the stock market trend next week?

牛牛課堂

Mar 4 17:09

Long-term answers | Your account on the left shrinks, while your right hand is chased by the times — Be the person that no bombardment can ever wipe out.